• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion


News provided by

Reportlinker

Mar 28, 2012, 04:30 ET

Share this article

Share this article


NEW YORK, March 28, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion

http://www.reportlinker.com/p0804703/Anti-Hypertensives-Market-to-2017---Patent-Expiries-of-Blockbusters-such-as-Diovan-Micardis-Avapro-and-Atacand-to-Accelerate-Erosion.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion", which provides insights into the anti-hypertensives therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of hypertension and pulmonary arterial hypertension. It also provides the share of generics in global anti-hypertensives and in each indication market. The report examines the global anti-hypertensives usage patterns. It includes the geographical distribution of hypertension and PAH disease markets across the US, the top five countries of Europe and in Japan. The report also includes insights into the anti-hypertensives Research and Development (R&D) product pipeline and explores the competitive landscape, including major players in the anti-hypertensives market. Finally, the report includes analysis on Mergers and Acquisitions (M&A) and licensing agreements that took place in the anti-hypertensives market.

GBI Research's analysis shows that the overall global anti-hypertensives market for two indications, hypertension and pulmonary arterial hypertension, was valued at $29.9 billion in 2010. It grew from $19.1 billion in 2002 at a CAGR of 5.8%. The market is expected to witness a fluctuation due to patent expiries followed by generic erosion and the possible launch of novel molecules. The market is expected to witness comparatively slow growth with a CAGR of 1.2% between 2010 and 2017, to reach $32.6 billion in 2017. A steady increase in the hypertension and PAH prevalence population and the use of fixed dose combination drugs will drive the growth of the anti-hypertensives market in the future. The market for hypertension market is expected to slow down due to patent expiries of major blockbuster drugs. Recent and upcoming patent expiries of drugs are the only barrier to the global anti-hypertensives market. However, the expected launch of novel molecules with disease modifying characteristics and better safety and efficacy will drive the market in the forecast period.

Scope

- The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the global anti-hypertensives market for two indications, hypertension and pulmonary arterial hypertension.

- Data and analysis on the anti-hypertensives market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain and Japan.

- Annualized market data for the anti-hypertensives market from 2002 to 2010, with forecasts to 2017.

- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.

- Share of the generics in global anti-hypertensives market and for the market of each indication that is covered in the report.

- Key drivers and restraints that have had a significant impact on the market.

- The competitive landscape of the global market including top companies benchmarking. The key companies studied in this report are Novartis, Daiichi Sankyo, Merck, Pfizer, AstraZeneca, Sanofi, Takeda and Boehringer Ingelheim.

- Key M&A activities and licensing agreements that took place between 2009 and 2011 in the anti-hypertensives market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -

- Align your product portfolio to the markets with high growth potential.

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Create a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.

- Develop market entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 7

2 Global Anti-Hypertensives Market - Introduction 9

2.1 GBI Research Report Guidance 10

3 Global Anti-Hypertensives Market - Market Overview 11

3.1 Introduction 11

3.2 Revenue Forecasts for the Global Anti-Hypertensives Market 12

3.2.1 Revenue 12

3.2.2 Annual Cost of Therapy 13

3.2.3 Treatment Usage Patterns 14

3.3 Anti-Hypertensives Market Drivers 19

3.3.1 Uptake of Fixed Dose Combination Therapies due to Better Efficacy in Hypertension and Pulmonary Arterial Hypertension 19

3.4 Anti-Hypertensives Market Restraints 19

3.4.1 Low Compliance in Hypertensive Patients 19

3.4.2 Patent Expiries of Major Blockbusters Including Diovan, Avapro, Blopress/Atacand, Cozaar/Hyzaar and Tracleer, Pose a Threat to Market Revenues 19

3.4.3 Low Treatment Seeking Behavior and Diagnosis in Pulmonary Arterial Hypertension 20

3.5 Generics Share in the Global Anti-Hypertensives Market 21

4 Global Anti-Hypertensives Market: Therapeutic Landscape 22

4.1 Hypertension 22

4.1.1 Introduction 22

4.1.2 Treatment Flow Algorithm for Hypertension 23

4.1.3 Revenue 23

4.1.4 Annual Cost of Therapy 25

4.1.5 Treatment Usage Patterns 27

4.1.6 Market Segmentation by Geography 32

4.2 Pulmonary Arterial Hypertension (PAH) Market 35

4.2.1 Introduction 35

4.2.2 Treatment Flow Algorithm for Pulmonary Arterial Hypertension 37

4.2.3 Revenue 38

4.2.4 Annual Cost of Therapy 39

4.2.5 Treatment Usage Patterns 40

4.2.6 Market Segmentation by Geography 45

5 Global Anti-Hypertensives Market - Geographical Landscape 48

5.1 Geographical Break-up 48

5.2 The US 51

5.2.1 Revenue 51

5.2.2 Annual Cost of Therapy 52

5.2.3 Treatment Usage Patterns 53

5.3 Top Five Countries in Europe 58

5.3.1 Revenue 58

5.3.2 Revenue by Country 59

5.3.3 Annual Cost of Therapy 60

5.3.4 Treatment Usage Patterns 62

5.4 Japan 67

5.4.1 Revenue 67

5.4.2 Annual Cost of Therapy 68

5.4.3 Treatment Usage Patterns 69

6 Global Anti-Hypertensives Market - Pipeline Analysis 74

6.1 Introduction 74

6.1.1 Research and Development Pipeline - Hypertension 76

6.1.2 Research and Development Pipeline - Pulmonary Arterial Hypertension 80

6.2 Profiles of Key Late-Stage Drugs in the Anti-Hypertension Market 83

6.2.1 SPP635 83

6.2.2 Pioglitazone 83

6.2.3 LCZ696 84

6.2.4 QT1571 (Imatinib) 85

6.2.5 Selexipag (NS-304, ACT-293987) 86

6.2.6 PS-433540 (DARA) 86

6.2.7 Macitentan (ACT-064992, Actelion 1) 87

6.2.8 Riociguat (BAY63-2521) 88

7 Global Anti-Hypertensives Market - Competitive Landscape 90

7.1 Market Share Analysis 90

7.2 Competitive Profiling 91

7.2.1 Novartis 91

7.2.2 Merck 92

7.2.3 Daiichi Sankyo 93

7.2.4 Sanofi 94

7.2.5 AstraZeneca 95

7.2.6 United Therapeutics 97

7.2.7 Actelion 98

7.2.8 Pfizer 100

8 Global Anti-Hypertensives Market - Strategic Consolidations 102

8.1 Overview 102

8.2 Deals by Type 102

8.2.1 M&A Deals by Indication 103

8.2.2 M&A Deals by Year 103

8.2.3 M&A Deals by Geography 104

8.2.4 Summary of Major M&A Deals 105

8.3 R&D Licensing Agreements 107

8.3.1 Licensing Agreements by Indication 107

8.3.2 Licensing Agreements by Phase 108

8.3.3 Licensing Agreements by Geography 108

8.3.4 Licensing Agreements for Drugs in Phase II and Phase III Stage 109

8.3.5 Licensing Agreements for Approved Drugs 110

9 Global Anti-Hypertensives Market - Appendix 112

9.1 Market Definitions 112

9.2 Abbreviations 112

9.3 Research Methodology 114

9.3.1 Coverage 114

9.3.2 Secondary Research 114

9.3.3 Primary Research 114

9.3.4 Therapeutic Landscape 115

9.3.5 Market Size by Geography 116

9.3.6 Geographical Landscape 118

9.3.7 Pipeline Analysis 118

9.3.8 Competitive Landscape 118

9.3.9 Expert Panel Validation 118

9.4 Contact Us 118

9.5 Disclaimer 118

9.6 Sources 119

1.1 List of Tables

Table 1: Anti-Hypertensives Market, Global, Revenue ($bn), 2002-2010 12

Table 2: Anti-Hypertensives Market, Global, Revenue Forecasts ($bn), 2010-2017 12

Table 3: Anti-Hypertensives Market, Global, Annual Cost of Therapy ($), 2002–2010 13

Table 4: Anti-Hypertensives Market, Global, Annual Cost of Therapy ($), 2010–2017 13

Table 5: Anti-Hypertensives Market, Global, Treatment Usage Patterns (millions), 2002–2010 14

Table 6: Anti-Hypertensives Market, Global, Treatment Usage Patterns (millions), 2010–2017 15

Table 7: Hypertension Therapeutics Market, Global, Revenue ($bn), 2002–2010 24

Table 8: Hypertension Therapeutics Market, Global, Revenue Forecasts ($bn), 2010–2017 24

Table 9: Hypertension Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2010 26

Table 10: Hypertension Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 26

Table 11: Hypertension Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2010 27

Table 12: Hypertension Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010–2017 28

Table 13: Hypertension Therapeutics Market, Global, Market Segmentation by Geography ($bn), 2002–2010 33

Table 14: Hypertension Therapeutics Market, Global, Market Segmentation by Geography ($bn), 2010–2017 34

Table 15: PAH Therapeutics Market, Global, Revenue ($m), 2002–2010 38

Table 16: PAH Therapeutics Market, Global, Revenue Forecasts ($m), 2010–2017 38

Table 17: PAH Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 39

Table 18: PAH Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 39

Table 19: PAH Therapeutics Market, Global, Treatment Usage Patterns (thousand), 2002–2010 40

Table 20: PAH Therapeutics Market, Global, Treatment Usage Patterns (thousand), 2010–2017 41

Table 21: PAH Therapeutics Market, Global, Market Segmentation by Geography ($m), 2002–2010 46

Table 22: PAH Therapeutics Market, Global, Market Segmentation by Geography ($m), 2010–2017 47

Table 23: Anti-Hypertensives Market, Global, Revenue by Geography ($bn), 2002–2010 49

Table 24: Anti-Hypertensives Market, Global, Revenue Forecasts by Geography ($bn), 2010–2017 50

Table 25: Anti-Hypertensives Market, The US, Revenue ($bn), 2002–2010 51

Table 26: Anti-Hypertensives Market, The US, Revenue Forecasts ($bn), 2010–2017 51

Table 27: Anti-Hypertensives Market, The US, Annual Cost of Therapy ($), 2002–2010 52

Table 28: Anti-Hypertensives Market, The US, Annual Cost of Therapy ($), 2010–2017 52

Table 29: Anti-Hypertensives Market, The US, Treatment Usage Patterns (millions), 2002–2010 53

Table 30: Anti-Hypertensives Market, The US, Treatment Usage Patterns (millions), 2010–2017 54

Table 31: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue ($bn), 2002–2010 58

Table 32: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2010–2017 59

Table 33: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue by Country ($bn), 2002–2010 59

Table 34: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue Forecasts by Country ($bn), 2010–2017 60

Table 35: Anti-Hypertensives Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002–2010 61

Table 36: Anti-Hypertensives Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010–2017 61

Table 37: Anti-Hypertensives Market, Top Five Countries in Europe, Treatment Usage Patterns (millions), 2002–2010 62

Table 38: Anti-Hypertensives Market, Top Five Countries in Europe, Treatment Usage Patterns (millions), 2010–2017 63

Table 39: Anti-Hypertensives Market, Japan, Revenue ($bn), 2002–2010 67

Table 40: Anti-Hypertensives Market, Japan, Revenue Forecasts ($bn), 2010–2017 67

Table 41: Anti-Hypertensives Market, Japan, Annual Cost of Therapy ($), 2002–2010 68

Table 42: Anti-Hypertensives Market, Japan, Annual Cost of Therapy ($), 2010–2017 68

Table 43: Anti-Hypertensives Market, Japan, Treatment Usage Patterns (millions), 2002–2010 69

Table 44: Anti-Hypertensives Market, Japan, Treatment Usage Patterns (millions), 2010–2017 70

Table 45: Anti-Hypertensives Market, Global, R&D Pipeline by Phase in Hypertension Market, July 2011 77

Table 46: Anti-Hypertensives Market, Global, R&D Pipeline by Phase in Pulmonary Arterial Hypertension Market, 2011 81

Table 47: Anti-Hypertensives Market, Global, Major M&A Deals, 2005–2011 105

Table 48: Anti-Hypertensives Market, Global, Licensing Agreements for Drugs in Phase II and Phase III Stage, 2005–2011 109

Table 49: Anti-Hypertensives Market, Global, Licensing Agreements for Approved Drugs, 2005–2011 110

1.2 List of Figures

Figure 1: Anti-Hypertensives Market, Global, Drivers and Restraints, 2011 11

Figure 2: Anti-Hypertensives Market, Global, Revenue Forecasts ($bn), 2002–2017 12

Figure 3: Anti-Hypertensives Market, Global, Annual Cost of Therapy ($), 2002–2017 13

Figure 4: Anti-Hypertensives Market, Global, Treatment Usage Patterns (millions), 2002–2017 14

Figure 5: Anti-Hypertensives Market, Global, Diseased Population (millions), 2002–2017 15

Figure 6: Anti-Hypertensives Market, Global, Treatment-Seeking Population (millions), 2002–2017 16

Figure 7: Anti-Hypertensives Market, Global, Diagnosed Population (millions), 2002–2017 17

Figure 8: Anti-Hypertensives Market, Global, Prescription Population (millions), 2002–2017 18

Figure 9: Anti-Hypertensives Market, Global, Branded versus Generic Market Share (%), 2010 21

Figure 10: Anti-Hypertensives Market, Treatment Flow Algorithm for Hypertension, 2011 23

Figure 11: Hypertension Therapeutics Market, Global, Revenue Forecasts ($bn), 2002–2017 24

Figure 12: Hypertension Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2017 25

Figure 13: Hypertension Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2017 27

Figure 14: Hypertension Therapeutics Market, Global, Diseased Population (millions), 2002–2017 28

Figure 15: Hypertension Therapeutics Market, Global, Treatment-Seeking Population (millions), 2002–2017 29

Figure 16: Hypertension Therapeutics Market, Global, Diagnosis Population (millions), 2002–2017 30

Figure 17: Hypertension Therapeutics Market, Global, Prescription Population (millions), 2002–2017 31

Figure 18: Hypertension Therapeutics Market, Global, Market Segmentation by Geography (%), 2010 and 2017 32

Figure 19: Hypertension Therapeutics Market, Global, Market Segmentation by Geography ($bn), 2002–2017 33

Figure 20: PAH Therapeutics Market, Treatment Flow Algorithm for PAH, 2011 37

Figure 21: PAH Therapeutics Market, Global, Revenue Forecasts ($m), 2002–2017 38

Figure 22: PAH Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2017 39

Figure 23: PAH Therapeutics Market, Global, Treatment Usage Patterns (thousand), 2002–2017 40

Figure 24: PAH Therapeutics Market, Global, Diseased Population (thousand), 2002–2017 41

Figure 25: PAH Therapeutics Market, Global, Treatment-Seeking Population (thousand), 2002–2017 42

Figure 26: PAH Therapeutics Market, Global, Diagnosed Population (thousand), 2002–2017 43

Figure 27: PAH Therapeutics Market, Global, Prescription Population (thousand), 2002–2017 44

Figure 28: PAH Therapeutics Market, Global, Market Segmentation by Geography (%), 2010 and 2017 45

Figure 29: PAH Therapeutics Market, Global, Market Segmentation by Geography ($bn), 2002–2017 46

Figure 30: Anti-Hypertensives Market, Global, Market Share by Geography (%), 2010 and 2017 48

Figure 31: Anti-Hypertensives Market, Global, Revenue Forecasts by Geography ($bn), 2002–2017 49

Figure 32: Anti-Hypertensives Market, The US, Revenue Forecasts ($bn), 2002–2017 51

Figure 33: Anti-Hypertensives Market, The US, Annual Cost of Therapy ($), 2002–2017 52

Figure 34: Anti-Hypertensives Market, The US, Treatment Usage Patterns (millions), 2002–2017 53

Figure 35: Anti-Hypertensives Market, The US, Diseased Population (millions), 2002–2017 54

Figure 36: Anti-Hypertensives Market, The US, Treatment-Seeking Population (millions), 2002–2017 55

Figure 37: Anti-Hypertensives Market, The US, Diagnosed Population (millions), 2002–2017 56

Figure 38: Anti-Hypertensives Market, The US, Prescription Population (millions), 2002–2017 57

Figure 39: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2002–2017 58

Figure 40: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue Forecasts by Country, ($bn), 2002-2017 59

Figure 41: Anti-Hypertensives Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002–2017 61

Figure 42: Anti-Hypertensives Market, Top Five Countries in Europe, Treatment Usage Patterns (millions), 2002–2017 62

Figure 43: Anti-Hypertensives Market, Top Five Countries in Europe, Diseased Population (millions), 2002–2017 63

Figure 44: Anti-Hypertensives Market, Top Five Countries in Europe, Treatment-Seeking Population (millions), 2002–2017 64

Figure 45: Anti-Hypertensives Market, Top Five Countries in Europe, Diagnosed Population (millions), 2002–2017 65

Figure 46: Anti-Hypertensives Market, Top Five Countries in Europe, Prescription Population (millions), 2002–2017 66

Figure 47: Anti-Hypertensives Market, Japan, Revenue Forecasts ($bn), 2002–2017 67

Figure 48: Anti-Hypertensives Market, Japan, Annual Cost of Therapy ($), 2002–2017 68

Figure 49: Anti-Hypertensives Market, Japan, Treatment Usage Patterns (millions), 2002–2017 69

Figure 50: Anti-Hypertensives Market, Japan, Diseased Population (millions), 2002–2017 70

Figure 51: Anti-Hypertensives Market, Japan, Treatment-Seeking Population (millions), 2002–2017 71

Figure 52: Anti-Hypertensives Market, Japan, Diagnosed Population (millions), 2002–2017 72

Figure 53: Anti-Hypertensives Market, Japan, Prescription Population (millions), 2002–2017 73

Figure 54: Anti-Hypertensives Market, Global, R&D Pipeline by Indication (%), 2011 74

Figure 55: Anti-Hypertensives Market, Global, R&D Pipeline by Phase (%), 2011 75

Figure 56: Anti-Hypertensives Market, Global, R&D Pipeline by Phase in Hypertension Market (%), 2011 76

Figure 57: Anti-Hypertensives Market, Global, R&D Pipeline by Phase in Pulmonary Arterial Hypertension Market (%), 2011 80

Figure 58: Anti-Hypertensives Market, Global, Market Share by Company (%), 2010 90

Figure 59: Anti-Hypertensives Market, Global, SWOT – Novartis, 2011 92

Figure 60: Anti-Hypertensives Market, Global, SWOT – Merck, 2011 93

Figure 61: Anti-Hypertensives Market, Global, SWOT – Daiichi Sankyo, 2011 94

Figure 62: Anti-Hypertensives Market, Global, SWOT – Sanofi, 2011 95

Figure 63: Anti-Hypertensives Market, Global, SWOT – AstraZeneca, 2011 96

Figure 64: Anti-Hypertensives Market, Global, SWOT – United Therapeutics, 2011 98

Figure 65: Anti-Hypertensives Market, Global, SWOT – Actelion Ltd, 2011 100

Figure 66: Anti-Hypertensives Market, Global, SWOT – Pfizer, 2011 101

Figure 67: Anti-Hypertensives Market, Global, Deals by Type (%), 2005–2011 102

Figure 68: Anti-Hypertensives Market, Global, M&A Deals by Year, 2005–2011 103

Figure 69: Anti-Hypertensives Market, Global, M&A Deals by Geography, 2005–2011 104

Figure 70: Anti-Hypertensives Market, Global, Major Licensing Agreements by Indication (%), 2005–2011 107

Figure 71: Anti-Hypertensives Market, Global, Major Licensing Agreements by Phase (%), 2005–2011 108

Figure 72: Anti-Hypertensives Market, Global, Major Licensing Agreements by Geography (%), 2005–2011 108

Figure 73: GBI Research Market Forecasting Model 117

Companies mentioned

Novartis

Merck

Daiichi Sankyo

Sanofi

AstraZeneca

United Therapeutics

Actelion

Pfizer

To order this report:

Therapy Industry: Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.